1 Rodriguez-Ruiz, M. E., Vitale, I., Harrington, K. J., Melero, I. & Galluzzi, L. Immunological impact of cell death signaling driven by radiation on the tumor microenvironment. Nat Immunol 21, 120-134, doi:10.1038/s41590-019-0561-4 (2020).
2 Wennerberg, E. et al. Immune recognition of irradiated cancer cells. Immunol Rev 280, 220-230, doi:10.1111/imr.12568 (2017).
3 Vanpouille-Box, C. et al. DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity. Nat Commun 8, 15618, doi:10.1038/ncomms15618 (2017).
4 Grapin, M. et al. Optimized fractionated radiotherapy with anti-PD-L1 and anti-TIGIT: a promising new combination. J Immunother Cancer 7, 160, doi:10.1186/s40425-019-0634-9 (2019).
5 Laurent, P. A. et al. In-vivo and in-vitro impact of high-dose rate radiotherapy using flattening-filter-free beams on the anti-tumor immune response. Clin Transl Radiat Oncol 24, 116-122, doi:10.1016/j.ctro.2020.07.004 (2020).
6 Spina, C. S. et al. Differential Immune Modulation With Carbon-Ion Versus Photon Therapy. Int J Radiat Oncol Biol Phys, doi:10.1016/j.ijrobp.2020.09.053 (2020).
7 Grau, C., Durante, M., Georg, D., Langendijk, J. A. & Weber, D. C. Particle therapy in Europe. Mol Oncol 14, 1492-1499, doi:10.1002/1878-0261.12677 (2020).
8 Tommasino, F. & Durante, M. Proton radiobiology. Cancers (Basel) 7, 353-381, doi:10.3390/cancers7010353 (2015).
9 Durante, M. New challenges in high-energy particle radiobiology. Br J Radiol 87, 20130626, doi:10.1259/bjr.20130626 (2014).
10 Durante, M. & Formenti, S. Harnessing radiation to improve immunotherapy: better with particles? Br J Radiol 93, 20190224, doi:10.1259/bjr.20190224 (2020).
11 Ebner, D. K. et al. The Immunoregulatory Potential of Particle Radiation in Cancer Therapy. Front Immunol 8, 99, doi:10.3389/fimmu.2017.00099 (2017).
12 Durante, M., Orecchia, R. & Loeffler, J. S. Charged-particle therapy in cancer: clinical uses and future perspectives. Nat Rev Clin Oncol 14, 483-495, doi:10.1038/nrclinonc.2017.30 (2017).
13 Dunn, G. P., Koebel, C. M. & Schreiber, R. D. Interferons, immunity and cancer immunoediting. Nat Rev Immunol 6, 836-848, doi:10.1038/nri1961 (2006).
14 Gajewski, T. F., Schreiber, H. & Fu, Y. X. Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol 14, 1014-1022, doi:10.1038/ni.2703 (2013).
15 Cai, X., Chiu, Y. H. & Chen, Z. J. The cGAS-cGAMP-STING pathway of cytosolic DNA sensing and signaling. Mol Cell 54, 289-296, doi:10.1016/j.molcel.2014.03.040 (2014).
16 Chen, Q., Sun, L. & Chen, Z. J. Regulation and function of the cGAS-STING pathway of cytosolic DNA sensing. Nat Immunol 17, 1142-1149, doi:10.1038/ni.3558 (2016).
17 Biswas, S. K. et al. A distinct and unique transcriptional program expressed by tumor-associated macrophages (defective NF-kappaB and enhanced IRF-3/STAT1 activation). Blood 107, 2112-2122, doi:10.1182/blood-2005-01-0428 (2006).
18 Demaria, S. & Formenti, S. C. The abscopal effect 67 years later: from a side story to center stage. Br J Radiol 93, 20200042, doi:10.1259/bjr.20200042 (2020).
19 Rodriguez-Ruiz, M. E., Vanpouille-Box, C., Melero, I., Formenti, S. C. & Demaria, S. Immunological Mechanisms Responsible for Radiation-Induced Abscopal Effect. Trends Immunol 39, 644-655, doi:10.1016/j.it.2018.06.001 (2018).
20 Brenneman, R. J. et al. Abscopal Effect Following Proton Beam Radiotherapy in a Patient With Inoperable Metastatic Retroperitoneal Sarcoma. Front Oncol 9, 922, doi:10.3389/fonc.2019.00922 (2019).
21 Ngwa, W. et al. Using immunotherapy to boost the abscopal effect. Nat Rev Cancer 18, 313-322, doi:10.1038/nrc.2018.6 (2018).
22 Boustani, J., Grapin, M., Laurent, P. A., Apetoh, L. & Mirjolet, C. The 6th R of Radiobiology: Reactivation of Anti-Tumor Immune Response. Cancers (Basel) 11, doi:10.3390/cancers11060860 (2019).
23 Kabiljo, J., Laengle, J. & Bergmann, M. From threat to cure: understanding of virus-induced cell death leads to highly immunogenic oncolytic influenza viruses. Cell Death Discov 6, 48, doi:10.1038/s41420-020-0284-1 (2020).
24 Wennerberg, E. et al. Barriers to Radiation-Induced In Situ Tumor Vaccination. Front Immunol 8, 229, doi:10.3389/fimmu.2017.00229 (2017).
25 Tanaka, A. & Sakaguchi, S. Targeting Treg cells in cancer immunotherapy. Eur J Immunol 49, 1140-1146, doi:10.1002/eji.201847659 (2019).
26 Lee, H. J., Jr., Zeng, J. & Rengan, R. Proton beam therapy and immunotherapy: an emerging partnership for immune activation in non-small cell lung cancer. Transl Lung Cancer Res 7, 180-188, doi:10.21037/tlcr.2018.03.28 (2018).
27 Kumari, S. et al. Immunomodulatory Effects of Radiotherapy. Int J Mol Sci 21, doi:10.3390/ijms21218151 (2020).
28 Durante, M. & Formenti, S. C. Radiation-Induced Chromosomal Aberrations and Immunotherapy: Micronuclei, Cytosolic DNA, and Interferon-Production Pathway. Front Oncol 8, 192, doi:10.3389/fonc.2018.00192 (2018).
29 Constanzo, J., Vanstalle, M., Finck, C., Brasse, D. & Rousseau, M. Dosimetry and characterization of a 25-MeV proton beam line for preclinical radiobiology research. Med Phys 46, 2356-2362, doi:10.1002/mp.13512 (2019).
30 Bray, N. L., Pimentel, H., Melsted, P. & Pachter, L. Near-optimal probabilistic RNA-seq quantification. Nat Biotechnol 34, 525-527, doi:10.1038/nbt.3519 (2016).
31 Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol 15, 550, doi:10.1186/s13059-014-0550-8 (2014).
32 Zhu, A., Ibrahim, J. G. & Love, M. I. Heavy-tailed prior distributions for sequence count data: removing the noise and preserving large differences. Bioinformatics 35, 2084-2092, doi:10.1093/bioinformatics/bty895 (2019).
33 Raudvere, U. et al. g:Profiler: a web server for functional enrichment analysis and conversions of gene lists (2019 update). Nucleic Acids Res 47, W191-W198, doi:10.1093/nar/gkz369 (2019).